Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 8.98% and Operating profit at -28.80% over the last 5 years
2
The company has declared Negative results for the last 8 consecutive quarters
3
With ROE of 1.68%, it has a very expensive valuation with a 2.69 Price to Book Value
4
Market Beating Performance
Stock DNA
Pharmaceuticals & Biotechnology
CNY 3,436 Million (Mid Cap)
160.00
NA
0.26%
-0.41
1.68%
2.69
Revenue and Profits:
Net Sales:
59 Million
(Quarterly Results - Jun 2025)
Net Profit:
10 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-11.16%
0%
-11.16%
6 Months
4.11%
0%
4.11%
1 Year
31.08%
0%
31.08%
2 Years
-33.65%
0%
-33.65%
3 Years
-48.44%
0%
-48.44%
4 Years
-78.65%
0%
-78.65%
5 Years
-22.26%
0%
-22.26%
Jenkem Technology Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
8.98%
EBIT Growth (5y)
-28.80%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.40
Sales to Capital Employed (avg)
0.22
Tax Ratio
4.52%
Dividend Payout Ratio
30.41%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
27.93%
ROE (avg)
10.24%
Valuation key factors
Factor
Value
P/E Ratio
160
Industry P/E
Price to Book Value
2.69
EV to EBIT
232.06
EV to EBITDA
46.70
EV to Capital Employed
3.85
EV to Sales
13.03
PEG Ratio
NA
Dividend Yield
0.26%
ROCE (Latest)
1.66%
ROE (Latest)
1.68%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
59.40
68.00
-12.65%
Operating Profit (PBDIT) excl Other Income
19.70
21.50
-8.37%
Interest
0.10
0.10
Exceptional Items
1.80
1.60
12.50%
Consolidate Net Profit
10.20
11.90
-14.29%
Operating Profit Margin (Excl OI)
127.30%
136.80%
-0.95%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -12.65% vs 69.15% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is -14.29% vs 525.00% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
221.80
287.20
-22.77%
Operating Profit (PBDIT) excl Other Income
64.50
152.00
-57.57%
Interest
0.40
0.40
Exceptional Items
1.20
0.80
50.00%
Consolidate Net Profit
29.80
115.70
-74.24%
Operating Profit Margin (Excl OI)
77.60%
415.50%
-33.79%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -22.77% vs -28.68% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -74.24% vs -38.06% in Dec 2023
About Jenkem Technology Co., Ltd. 
Jenkem Technology Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






